CCCC Other Liab vs Other Stockholder Equity Analysis
| CCCC Stock | USD 6.06 0.02 0.33% |
C4 Therapeutics financial indicator trend analysis is way more than just evaluating C4 Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether C4 Therapeutics is a good investment. Please check the relationship between C4 Therapeutics Other Liab and its Other Stockholder Equity accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in C4 Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.
Other Liab vs Other Stockholder Equity
Other Liab vs Other Stockholder Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of C4 Therapeutics Other Liab account and Other Stockholder Equity. At this time, the significance of the direction appears to have pay attention.
The correlation between C4 Therapeutics' Other Liab and Other Stockholder Equity is -0.99. Overlapping area represents the amount of variation of Other Liab that can explain the historical movement of Other Stockholder Equity in the same time period over historical financial statements of C4 Therapeutics, assuming nothing else is changed. The correlation between historical values of C4 Therapeutics' Other Liab and Other Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Liab of C4 Therapeutics are associated (or correlated) with its Other Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Stockholder Equity has no effect on the direction of Other Liab i.e., C4 Therapeutics' Other Liab and Other Stockholder Equity go up and down completely randomly.
Correlation Coefficient | -0.99 |
| Relationship Direction | Negative |
| Relationship Strength | Significant |
Other Liab
Other Stockholder Equity
Most indicators from C4 Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into C4 Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in C4 Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.At present, C4 Therapeutics' Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 2.13, whereas Selling General Administrative is forecasted to decline to about 27.4 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 2.9M | 7.6M | 7.7M | 4.4M | Interest Income | 387K | 3.6M | 8.6M | 9.0M |
C4 Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
C4 Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
C4 Therapeutics fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 118.3M | 400.1M | 506.8M | 430.8M | 376.5M | 362.8M | |
| Short Long Term Debt Total | 13.7M | 22.9M | 42.9M | 87.2M | 71.0M | 46.2M | |
| Other Current Liab | 6.7M | 9.5M | 13.6M | 2.9M | 20.6M | 21.7M | |
| Total Current Liabilities | 33.6M | 43.9M | 51.2M | 44.5M | 42.8M | 44M | |
| Total Stockholder Equity | (112.0M) | 280.8M | 389.6M | 289.2M | 246.1M | 185.9M | |
| Other Liab | 72.7M | 53.6M | 24.4M | 16.9M | 15.2M | 14.4M | |
| Net Tangible Assets | (112.0M) | 280.8M | 389.6M | 289.2M | 332.6M | 168.9M | |
| Property Plant And Equipment Net | 18.9M | 16.6M | 35.1M | 77.5M | 71.1M | 43.9M | |
| Current Deferred Revenue | 20.7M | 27.6M | 31.8M | 33.5M | 15.5M | 27.2M | |
| Net Debt | (76.8M) | (158.8M) | (33.2M) | 57.4M | (55.6M) | (58.4M) | |
| Retained Earnings | (117.5M) | (183.8M) | (267.7M) | (395.9M) | (528.4M) | (502.0M) | |
| Accounts Payable | 5.4M | 5.7M | 4.5M | 1.2M | 1.4M | 2.6M | |
| Cash | 90.5M | 181.7M | 76.1M | 29.8M | 126.6M | 99.2M | |
| Non Current Assets Total | 21.5M | 19.1M | 181.1M | 143.3M | 105.3M | 90.4M | |
| Cash And Short Term Investments | 90.5M | 371.7M | 309.3M | 337.1M | 253.7M | 256.4M | |
| Net Receivables | 4.6M | 4.5M | 5.7M | 1.5M | 11.8M | 15.3M | |
| Common Stock Shares Outstanding | 43.0M | 43.1M | 46.0M | 48.9M | 49.6M | 45.0M | |
| Liabilities And Stockholders Equity | 118.3M | 400.1M | 506.8M | 430.8M | 376.5M | 362.8M | |
| Non Current Liabilities Total | 196.6M | 75.5M | 65.9M | 97.1M | 87.6M | 96.7M | |
| Capital Lease Obligations | 13.7M | 12.9M | 32.1M | 75.7M | 71.0M | 40.3M | |
| Other Current Assets | 1.6M | 4.8M | 10.7M | 9.9M | 5.7M | 6.2M | |
| Other Stockholder Equity | (105.5M) | 64.5M | 658.1M | 689.3M | 774.6M | 813.3M | |
| Total Liab | 230.2M | 119.3M | 117.2M | 141.6M | 130.3M | 128.7M | |
| Net Invested Capital | (112.0M) | 290.8M | 400.4M | 300.7M | 246.1M | 191.8M | |
| Property Plant And Equipment Gross | 18.9M | 16.6M | 42.0M | 85.6M | 78.9M | 48.1M | |
| Total Current Assets | 96.8M | 381.0M | 325.7M | 287.6M | 271.2M | 272.4M | |
| Accumulated Other Comprehensive Income | (1K) | 13K | (775K) | (4.1M) | (127K) | (133.4K) | |
| Net Working Capital | 63.1M | 337.2M | 274.4M | 243.0M | 228.4M | 228.4M | |
| Short Term Debt | 880K | 1.0M | 1.3M | 7.0M | 5.2M | 3.0M | |
| Property Plant Equipment | 18.9M | 16.6M | 3.1M | 7.4M | 6.7M | 10.6M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether C4 Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of C4 Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of C4 Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on C4 Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in C4 Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of C4 Therapeutics. If investors know CCCC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about C4 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.71) | Revenue Per Share 0.522 | Quarterly Revenue Growth 0.387 | Return On Assets (0.21) | Return On Equity (0.46) |
The market value of C4 Therapeutics is measured differently than its book value, which is the value of CCCC that is recorded on the company's balance sheet. Investors also form their own opinion of C4 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is C4 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because C4 Therapeutics' market value can be influenced by many factors that don't directly affect C4 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between C4 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if C4 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, C4 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.